Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Astria Therapeutics, Inc. (NASDAQ: ATXS)*, formerly, Catabasis Pharmaceuticals (NASDAQ:CATB)

Organization & Developments: Catabasis

Parents

Astria Therapeutics, Inc. (NASDAQ: ATXS)*, formerly, Catabasis Pharmaceuticals (NASDAQ:CATB)

*Biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other well-characterized compounds to create dual action medicines for the treatment of inflammatory and metabolic diseases
*These therapies are derived from the Company's SMART Linker technology platform and exhibit mechanistic synergy on the targeted disease pathway
*Utilizing its expertise in pathway pharmacology to develop a pipeline of medicines for metabolic and inflammatory diseases.
2018: Catabasis slashes 42% of staff to 'focus resources' on edasalonexent
2019: Catabasis Pharmaceuticals: My Long Thesis And Analysis_seekingalpha.com
2020: Catabasis Pharmaceuticals: Accumulating Ahead Of Edasalonexent's Top-Line Results
2021: Can't Get My Head Around Catabasis Pharmaceuticals
2021: Catabasis Pharmaceuticals no more: Meet Astria Therapeutics, hoping to be a phoenix from the flames
2023: Astria Therapeutics’ edge in an ultra-rare disease
2024: Astria teams up with Ypsomed to develop autoinjector for STAR-0215
2024: Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
2024: Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
2024: Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema_ seekingalpha.com
2024: STAR-0215 reduces HAE attacks over 90% in early trial, data show
2025: Astria Therapeutics: A High-Conviction Bet On HAE